Oral administration of levodopa (LD) is the gold standard in managing Parkinson’s disease (PD). Although LD is the most effective drug in treating PD, chronic administration of LD induced dyskinesia. In commercial oral formulations, LD is co-administrated with an AADC inhibitor (carbidopa) and a COMT inhibitor (entacapone) to enhance its bioavailability. During the last few years, the potential application of molecularly imprinted polymers (MIPs) in drug delivery has received considerable attention. To achieve a prolonged release of LD with the aim of improving its bioavailability, naturally based MIP with LD developed and characterized. In vitro study was showed a prolonged delivery of LD that is void of the plasma concentration fluctuations observed for the control (commercial formulation). At the same time, measurements of LD and dopamine of rats administered with this formulation showed enhanced bioavailability of LD.
